When Lorne Blahut was diagnosed with HIV in 2000, he thought he was going to die. But experts at The Ottawa Hospital, armed with incredible advances in research, had a different plan. Then in 2017, he again found himself face-to-face with another significant health scare — prostate cancer. But Lorne knew he was in good hands.

“Several years ago, my doctor, Stephen Kravcik, told me, ‘You better start planning for your retirement, because you’re not going to die,’” said Lorne. And he was right. The 67-year-old retired 7 years ago from a career at Canada Mortgage and Housing Corporation.

Lorne’s original fears of dying when first diagnosed with HIV were well founded. It is estimated that more than 32 million people have died from HIV since the early 1980s and the high fatality rates from early-on in the epidemic remained staggering for years. But then research turned the tide.

Excellence in research

“Certainly, the mid-90s was the heyday of HIV research when new drugs were developed. The Ottawa Hospital group did revolutionary research led by Drs. Bill Cameron and Jonathan Angel,” said Dr. Kravcik, who came to The Ottawa Hospital in 1994 specifically to do HIV research and clinical trials for new drugs under the guidance of Dr. Cameron. He said at that time about 125 of their HIV patients passed away every year.

Today, HIV is no longer a death sentence.

“It’s not even a chronic disease. Most people like Lorne take one or two pills a day and their lives are totally normal. The pills are superb. They are well-tolerated and with them patients do really, really well.” – Dr. Stephen Kravcik

Lorne Blahut grateful for care received at The Ottawa Hospital
Lorne Blahut grateful for care received at The Ottawa Hospital.

When Lorne was first diagnosed 20 years ago, patients diagnosed with HIV/AIDS were living longer thanks to the antiretroviral medications, but it wasn’t common for patients to survive for decades.

“Being diagnosed was a horrific shock,” said Lorne. “And for a while I kept the diagnosis to myself. Being in the gay community, there was the fear that people were going to find out. It was intimidating, it was daunting, but there’s the saying that your worst fears are only realized in your head.”

Lorne’s fears proved unfounded when he realized he was in competent, caring hands.

Helping patients navigate their disease

Dr. Kravcik
Dr. Stephen Kravcik

“A number of people helped navigate the whole disease piece. There was a team around from the beginning,” said Lorne. “Dr. Kravcik explained what was going to happen with the various medications and took the time to listen when I asked for clarification. Kim Lancaster, the social worker on the team, helped with the initial diagnosis, with moving forward, and with issues I was dealing with personally.”

Kim Lancaster, who worked in the infectious diseases clinic for nine years, said the main stay of her job was helping people emotionally manage the impact of receiving an HIV positive diagnosis, and helping them figure out how to conduct themselves in their professional, social, and emotional lives. She said there’s still such a stigma attached to the disease.

“Lorne knew he needed help and was courageous to reach out his hand like that,” said Kim. “In the HIV world, many of the people who don’t live well with the disease are those who are too mired in shame, or fearful of discrimination, to access medical and psychosocial support. They don’t invite people into their medical experience.”

“The care was all encompassing. I’ve not only been looked after physically – bodily – but also, I have had mental support.” – Lorne Blahut

Lorne said the numerous levels of care he received during his treatment in the early years helped him cope with having an illness that is so stigmatized. He also benefited greatly from the research conducted at the hospital, and the antiretroviral drugs developed over the years to keep the disease in remission. Lorne survived. Then he suddenly found himself faced with another life-threatening disease – prostate cancer.

“When you get a diagnosis of cancer, it takes a while to sink in,” said Lorne. But he wanted to be informed about his treatment options.

Minimally-invasive robotic procedure

Lorne read up on the two prostate cancer surgery options before deciding that the robotic surgery, offered at The Ottawa Hospital, was the right one for him. The da Vinci Surgical System is a state-of-the-art robotic system that the surgeon operates remotely, using cameras and tiny surgical instruments. This operation is easier to recover from because it is performed through small incisions rather than the traditional larger incision in the lower abdomen. The Ottawa Hospital was the third hospital in Canada to acquire this minimally invasive surgical system, which was purchased with funding from the community.

The da Vinci Surgical System is a state-of-the-art robotic system
The da Vinci Surgical System, a state-of-the-art robotic system

“What particularly struck me when comparing the two surgeries was the recovery. The recovery time is longer with the traditional operation because of the significant incision the surgeon has to make, and you wear a catheter for months. There is also a tendency for there to be more nerve damage because it’s not as precise. So, for me it was a no brainer.”

Preparing for surgery

Lorne met with surgeon Dr. Chris Morash, who talked about the possible side effects of prostate cancer surgery. Some individuals experience incontinence and/or sexual dysfunction and some might require hormone therapy after the surgery. Several days later, Lorne met with social worker Liane Murphy and expressed his concerns about all of this.

Liane meets with individuals diagnosed with prostate cancer to help them prepare for their surgery and recovery and to talk through any of their concerns.  Her advocacy on Lorne’s behalf led to a positive pre-operation discussion with Dr. Morash who better addressed Lorne’s concerns.  In February 2018, Lorne underwent three-hour robotic surgery. He recovered well and is back to enjoying retirement.

World-class care, right here at home

“I moved here in 1992.  When I retired seven years ago, someone asked me if I was going to move back to Saskatchewan. First thing that came to mind was, ‘I won’t because I can’t get the healthcare I get at The Ottawa Hospital,’” said Lorne. “Overall, my experience with The Ottawa Hospital has been exemplary. The staff has treated me well and been very supportive. I can’t brag enough about them.”

Lorne is certainly not alone in navigating through the diagnoses and treatment of HIV and prostate cancer. Many men go through similar experiences with these diseases. But when it comes to HIV, Lorne is also trailblazing a new domain in healthcare.

“We don’t have a lot of men his age who have survived HIV,” said Tim Hutchinson, former Director of Social Services at The Ottawa Hospital Cancer Centre who has known Lorne for many years. “He’s a pioneer and role model in what happens next as this population ages, and how it is as a gay man, navigating a healthcare system.”

The Ottawa Hospital is establishing a Research Chair in Gay Men’s Health to create a comprehensive healthcare agenda that will help improve access to, and delivery of gay-relevant healthcare for men of all ages.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Published July 2020

We each have a defining moment in our life — a moment that changes our life forever. For some, that moment is not as clearly defined as it is for others. For Kimberly Mountain, that moment was the discovery of a cancerous brain tumour.

In February, 2011, Kimberly was 28 years old and out with her then-boyfriend, Matt Mountain, when she felt a weird, strong twitch on the right side of her face as they were driving. “Then all I remember is waking up. Our car was pulled over on the side of the highway. Paramedics were there, and I heard Matt say, ‘Kim just had a seizure’,” recalls Kimberly.

Kimberly was rushed by ambulance to the trauma centre at the Civic Campus of The Ottawa Hospital. She would have another seizure, and then an MRI revealed a brain tumour on her right frontal lobe. That moment changed her life.

For two weeks, The Ottawa Hospital became Kimberly’s second home. Her family and Matt never left her side. “Oddly enough, my memories of being in the hospital aren’t of a sad time at all. They are actually some of my favourite memories, filled with friends and family. Everyone I loved was there. And we made friends with the amazing nurses and staff,” says Kimberly.

Awake brain surgery

Kimberly Mountain at The Ottawa Hospital

On March 7, 2011, Kimberly had brain surgery. Her surgeon, Dr. Charles Agbi, would keep her awake for the operation. This is a highly specialized surgical procedure that requires a team approach led by an experienced neurosurgeon and a neuroanesthesiologist. It enables the neurosurgeon to remove tumours that would otherwise be inoperable because they are too close to areas of the brain that control vision, language, and body movement. Regular surgery could result in a significant loss of function. By keeping Kimberly awake, the medical team was able to ask her to move certain body parts and speak during the procedure.

When she thinks back to the operation, she remembers never being worried. “I guess the hospital staff had made me feel safe and confident.”

During surgery, Kimberly could feel the vibrations of the team drilling into her head, but she didn’t mind it. “I kept talking, laughing, and singing Disney songs, like “Hakuna Matata.” I was telling them how I was going to go to Disney World when it was over. Five hours seemed like just one,” says Kimberly.

For Dr. Agbi, this type of interaction is critical to the success of the surgery. “If they’re only answering questions [surgery staff] are asking them, sometimes we might miss something.”

Transformational technology

It is advances in technology like Kimberly experienced that allow neurosurgeons at The Ottawa Hospital to provide transformational care.

In fact, donor support brought a specialized microscope to Ottawa, allowing surgeons to perform fluorescence-guided surgery. The technique requires patients to drink a liquid containing 5-aminolevulinic acid (5-ALA) several hours before surgery. The liquid concentrates in the cancerous tissue and not in normal brain tissue. As a result, malignant gliomas “glow” a fluorescent pink color under a special blue wavelength of light generated by the microscope. This allows surgeons to completely remove the tumour in many more patients, with recent studies showing that this can now be achieved in 70 percent of surgeries compared to the previous 30 percent average. The first surgery of this kind in Canada was performed at The Ottawa Hospital.

“Dr. Nicholas sat down, held my hand, and said the word — cancer. Everything went blurry, and this time I couldn’t stop the tears. I had been strong up until that moment.” – Kimberly Mountain

Oncologist reveals brain tumour is cancerous

When pathology tests on the tumour came back several weeks later, Kimberly met with her oncologist, Dr. Garth Nicholas, and he revealed the news she feared the most. “Dr. Nicholas sat down, held my hand, and said the word — cancer. Everything went blurry, and this time I couldn’t stop the tears. I had been strong up until that moment,” remembers Kimberly.

Kimberly Mountain

During her cancer treatment, Kimberly faced 30 rounds of radiation, followed by chemotherapy. Matt, who had proposed during Kim’s long stay in the hospital, took her on trips to amusement parks or convertible drives to help get her through the difficult times. The couple even made a special trip to Disney World. “All I could think of during my brain surgery was how happy and carefree it was there. The world was suddenly much more exciting, and I was aware of every little smell, feeling, and moment—something I think maybe only cancer patients can appreciate.”

This all provided Kimberly with a distraction from the side effects, the tiredness, and the hair loss. Losing her hair was one of the most difficult parts of treatment. “I hated losing my long, beautiful hair.”

Less than a year later, on January 6, 2012, Kimberly received her last chemotherapy treatment. “I asked those pills to eat that cancer.” Her wish would be realized when an MRI could not detect any residual cancer. Kimberly transformed into a cancer survivor.

Kim Mountain and her family as she rings the bell.

Through a mother’s eyes

Kimberly has become known for never showing up for an appointment without a small contingent of supporters. She always has her family by her side, including her mother, Cyndy Pearson. Cyndy laughs that Kimberly always has an entourage—even when she learned her tumour was cancerous. “We were all there. When there’s something important, we’re all there. When Dr. Garth Nicholas leaned over, and said, ‘Kim you have cancer,’ we were all crying.”

A mother and a daughter hugging
Kimberly Mountain and her mother, Cyndy Pearson

Cyndy is grateful to The Ottawa Hospital for saving Kimberly, her youngest of three children. She points out March 7, 2011 is a new date circled on the family’s calendar—Kimberley’s re-birthday.

Cyndy is also forever grateful for Dr. Agbi’s care. “If this surgery hadn’t happened, she wouldn’t be having any more birthdays. If the hospital had not been able to save her…” Cyndy’s voice trails off.

 
Kimberly Mountain

“Even if the cancer does come back, I am confident that The Ottawa Hospital will be able to save me again, thanks to its constant innovative research and clinical trials that are making treatment better and saving lives.” — Kimberly Mountain

Cancer survivor ten years later

Today, Kimberly has a tattoo on the back of her neck that reads “Hakuna Matata – March 7, 2011”. She celebrates every milestone — including being cancer free — with family, friends, and of course Matt, who never left her side and who is now her husband. You could say it’s like a Disney ending.

Not everything went back to normal. “My precious hair will never be the same,” says Kimberly. “There’s a big spot where my hair will never grow back. The whole right side of my head is permanently bald.” However, always finding the positive, Kimberly says she can do her hair in ten seconds these days, thanks to a few different wigs, “I may actually own more wigs than shoes.”

All joking aside, Kimberly is grateful for each day. “Even if the cancer does come back, I am confident that The Ottawa Hospital will be able to save me again, thanks to its constant innovative research and clinical trials that are making treatment better and saving lives.”

For now, Kimberly takes it one day at a time, celebrating life’s little moments each day.

Hear Kimberly Mountain on Pulse: The Ottawa Hospital Foundation Podcast.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

REthinking Clinical Trials (REaCT) is a unique research program aimed at improving the lives of people with cancer through patient-centred, pragmatic clinical trials.

Based at The Ottawa Hospital, the REaCT program engages patients and their loved ones in research every step of the way, from generating ideas to setting priorities to designing studies and sharing results.

Unlike most cancer clinical trials, which are focused on evaluating experimental treatments in a very narrow patient population, REaCT trials compare standard approved treatments in a real-world setting with a broad range of patients. In this way, REaCT trials can efficiently answer some of the most important questions for cancer patients and the health care system.

REaCT is the largest pragmatic cancer clinical trials program in Canada, with more than 2,700 patients participating in 17 clinical trials at 15 centres in Canada.

Gina Mertikas-Lavictoire grateful for her care at The Ottawa Hospital

“We are helping the future generation with every trial we do. I’m so thankful I was part of this trial.”

— Gina Mertikas-Lavictoire, REaCT trial participant

“Being diagnosed is pretty lifechanging. You feel for other women who are going through this, and so I wanted to give back for the care I was receiving to help other women. I was open to any treatment that was new and innovative. The REaCT trial procedures were straightforward and easy to understand.”

— Connie Chartrand, breast cancer patient, participated in three REaCT clinical trials

Surgeon-scientist Dr. Rebecca Auer is leading a world-first clinical trial that she hopes will protect cancer patients from COVID-19 and other respiratory infections by boosting their immune systems during treatment. The trial was funded in part thanks to donor support to the COVID-19 Emergency Response Fund.

“A cancer diagnosis is scary at the best of times, but the pandemic has made it even worse,” said Dr. Auer, surgical oncologist and Director of Cancer Research at The Ottawa Hospital and associate professor at the University of Ottawa. “Cancer patients have weakened immune systems, which makes them more likely to get severely ill from COVID-19.”

At best, a severe infection could delay a patient’s cancer treatment. At worst, it could kill them.

Patients receiving cancer treatments are the most at risk because the treatments further weaken their immune system. This at-risk population is quite large – over 90,000 people received radiotherapy or chemotherapy treatments in Ontario alone in 2019.

“While there are many specific vaccines for COVID-19 in the works, they won’t be available for at least a year. Cancer patients need protection now.” – Dr. Rebecca Auer

Boosting the immune system during treatment

Dr. Auer and her team at The Ottawa Hospital came up with the idea of testing whether boosting cancer patients’ immune systems during their treatment could help prevent COVID-19 and other respiratory infections. In collaboration with scientists at the Ontario Institute of Cancer Research, they explored an immune-stimulator called IMM-101. Then she worked with Canadian Cancer Trials Group at Queen’s University to design and run the clinical trial at nine cancer centres across Canada.

The researchers will recruit 1,500 patients currently receiving cancer treatment to this clinical trial. Patients will be randomly assigned to receive either regular care, or regular care plus IMM-101. This preparation of harmless heat-killed bacteria had been developed as an anti-cancer therapy because it stimulates the immune system. It has already been safely given to 300 advanced cancer patients in earlier trials.

Training the innate immune system

Dr. Rebecca Auer speaks with a colleague
Dr. Rebecca Auer speaks with a colleague (Photo taken before COVID-19)

This trial takes advantage of a lesser-known aspect of the immune system — innate immunity. This first-response arm of the immune system plays a key role in detecting viruses.

Innate immune cells recognize features that are common to many viruses, allowing them to attack viruses the body has never seen before. This is different from the adaptive immune system, which only recognizes viruses the body has already encountered through prior infection or through a vaccine.

The research team hopes that because the IMM-101 treatment can train the patient’s innate immune system, it will help to fight off the COVID-19 virus, in addition to other viruses that cause respiratory infections.

“There is good data to suggest that the reason some people have no symptoms from COVID-19 while others get very sick is their innate immune system’s ability to respond early and quickly to the virus. This made us consider whether we could use an innate immune booster to prevent COVID-19 infections.” – Dr. Rebecca Auer

Based on data from other immune stimulators, it’s likely that this immune-boost would be temporary. But researchers hope it will last long enough to get a patient through their cancer treatments. Once the treatments have ended, the patient’s immune system would return to its regular strength and be strong enough to fight off viruses on its own.

Protection from more than COVID-19

The advantage of this immune-boosting approach is that it could help cancer patients fight off all sorts of viruses while they are undergoing cancer treatments and are at their most vulnerable.

“The treatment we’re using trains the immune system to do a better job fighting the next viral infection,” said Dr. Auer. “It’s not specific to COVID-19, but actually applies to any viral respiratory illness.”

If successful, IMM-101 could also offer benefits to people with other chronic illnesses or compromised immune systems who are similarly at a heightened risk of serious outcomes from COVID-19. It could also help protect people with cancer from other respiratory infections like the seasonal flu.

Preparing for future pandemics

“In 20 years, we’ve had three coronavirus epidemics or pandemics –SARS, MERS and COVID-19—so it’s likely that we’ll see another,” said Dr. Auer.

“We think harnessing innate immunity could be one of our best weapons for fighting COVID-19 and could be easily adapted to tackle future pandemics.” – Dr. Rebecca Auer

Donate today to support promising research and clinical trials like this one.

Cancer patients undergoing active treatment who are interested in participating in this trial should speak with their cancer specialist.

The Ottawa Hospital Foundation provided seed funding for this project through the COVID-19 Emergency Response Fund, funded by generous donors in the community. Read about other projects that have received funding thanks to donor support and are making a difference in the fight against COVID-19.

Additional funding and in-kind support for this trial have been provided by the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Academic Medical Organization, ATGen NK Max Canada, and Immodulon Therapeutics, the manufacturer of IMM-101.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Exceptional care makes young mother want to give back

When Gina Mertikas-Lavictoire received the good news that she had gone from breast cancer patient to cancer survivor, she knew she wasn’t done with The Ottawa Hospital.

Eternally grateful for the care she received, Gina knew she wanted to give back — she felt that she needed to.

“After my treatment was done, I asked my oncologist, Dr. Mark Clemons — who’s one of the best doctors in the world — ‘how can I give back?’ I need to do something to give back.” – Gina Mertikas-Lavictoire

Gina was 34 years old with three young children at home, the youngest just 12 months old, when she felt something was wrong — there was an unusual firmness in one of her breasts. A breast cancer diagnosis followed and rocked her family’s world. She immediately went into survival mode. “The first thing I asked my doctor was when can I have a mastectomy and when can I start my treatment. I never looked back,” Gina says.

Despite the alarming health news, she faced the disease with sheer determination. “I received excellent care at The Breast Health Centre at The Ottawa Hospital. I went through chemotherapy and radiation. I’ve had four surgeries including a hysterectomy and a double mastectomy.”

An unimaginable experience for a young mother, but the gratitude Gina has for The Ottawa Hospital is undeniable in her desire to give back.

Paying it forward

Gina Mertikas and Katerina Mertikas
Gina and her mother, Katerina Mertikas, a renowned local artist

“When I received the news that I would be able to watch my children grow up, that’s when I put the wheels in motion to help others,” recalls Gina. She came up with the idea of selling a calendar to support cancer research at The Ottawa Hospital.

Today, she’s feeling great and is solely focused on her fundraising efforts, which have exceeded her wildest expectations.

“From the get go, the calendars kept selling out. They were just flying off the shelves. What I’m surprised by is the amount of support that I had, not only friends and family but from all of Ottawa and across the country. People are supportive. We’ve even shipped calendars into the United States,” says Gina.

Gina hasn’t done any of this alone. Right alongside her during her diagnosis, treatment, and now the furious fundraising efforts is her family, including her mother Katerina Mertikas. Katerina is a local artist, who is renowned across the country for her beautiful paintings. It’s Katerina’s art, which is featured each month in the calendar.

Research is transforming care

For Katerina, it was extraordinarily difficult to watch her daughter go through the treatment and surgeries. “There are no words,” says Katerina.

However, the mother of two knows cancer research played a role in helping her youngest daughter recover. “My own daughter has benefitted from research through the treatment she received, which was Herceptin — a chemotherapy drug. It was originally used in a clinical trial before becoming a standard of care for patients,” acknowledges Katerina. It’s for that reason this mother-daughter duo is working together to help others facing the disease.

With calendars from 2019 and 2020 under her belt, and $25,000 raised for cancer research, Gina wants to see this continue for years to come with the help of her own children. Her eldest daughter, Katerina, has been introduced to philanthropy and what it means to give back. For Gina, she’d love to one day hand off the calendar project to the next generation. “I’m hoping someday my kids will take over this calendar and it will continue on,” says the proud mother.

Excellence in care

For this family, there is undeniable gratitude toward the care team at The Ottawa Hospital, which helped Gina when her life depended on it. The impact has been profound on the family and for Katerina, especially from one doctor in particular — Dr. Mark Clemons, medical oncologist and associate scientist at The Ottawa Hospital Cancer Centre.

Dr. Clemons first joined The Ottawa Hospital in 2009 and has made a remarkable name for himself since, both among patients and colleagues alike. At the time, he was unsatisfied with the way breast cancer was being monitored and treated in Canada, so this quickly became his primary area of specialty for clinical trials.

In fact, in 2014, along with Dr. Dean Fergusson, Director of the Clinical Epidemiology Program, Dr. Clemons developed the Rethinking Clinical Trials or REaCT program as a way to make the process of enrolling in clinical trials easier and more efficient for cancer patients. As of June 2020, this groundbreaking program had enrolled over 2,600 patients, making it the largest pragmatic cancer trials program in Canada. In recognition of their success, the REaCT team recently earned a 2020 Research Excellence Team Award from The Ottawa Hospital. Dr. Clemons was also the recipient of the Chrétien Researcher of the Year Award in 2013.

For Gina, she is grateful to have been cared for by such an accomplished researcher who also happens to be a compassionate physician. Dr. Clemons offered guidance, encouragement and hope when she needed it most, and this inspired her to give back.

“Dr. Mark Clemons is a very special doctor,” says Katerina. “He made us feel so comfortable. He helped a lot with his attitude. He gave it his all — so how could we not give back? I wish we could give more.” – Gina Mertikas-Lavictoire

Listen to Pulse Podcast, and hear Gina’s story, including a special guest appearance by Dr. Mark Clemons.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Now available, in limited quantities, these stunning t-shirts are raising funds for The Craig Kulig Memorial Fund and cancer research at Ottawa Hospital.

We are hoping to send out a small ripple of Wearable Happiness – One t-shirt at a time with all proceeds going to The Craig Kulig Memorial Fund.

Note: Sizing is Unisex and generous for women.

Bright and spotted with champagne bubbles that effervesce from the earth, Darlene Kulig’s artworks are utterly joyful. Kulig refers to her style as semi- abstracted spirited landscape. Her stylized art builds on her experience as a graphic designer, and in each new painting she explores light, rhythm, color, and the life force of her subjects. The 12 images in this calendar reflect her home in Canada and her travels abroad.

 

Learn more about the Craig Kulig Memorial Fund supporting cancer research

Darlene’s signature style is described as semi-abstracted spirited landscape and her love of the beauty available in the Canadian landscape is clear. What is especially impressive is that she has developed a unique very personal approach that “feels” Canadian and is utterly joyful.

Darlene’s award winning work has been featured in North American publications and Global Affairs Canada has installed a selection of Kulig Canadian Landscapes in Canadian Embassies buildings around the world. The Mayo clinic has Darlene’s work hanging in the Rochester Clinic and Pomegranate Communications has licensed Darlene’s work in their international product line.

A member of the Etobicoke Art Group and Neilson Park Creative Centre where she studies and paints, you can find her work in galleries across Canada and the United States as well as private collections around the world.

Hope despite aggressive skin cancer diagnosis

Diagnosed with a stage 4 melanoma at the age of 62, Dan Collins feared for his life when he learned about the aggressive form of cancer. However, immunotherapy treatment gave him a reason to hold out hope. Dan had hope because of scientists who never gave up; who were determined to turn the tables on cancer and to create a better chance of survival, for patients like him. Hope that a cure is coming.

Discovery of a mass

Four years ago, Dan had been travelling for work, when he started noticing some pain when he’d lean his head back to rest on the plane. He recalls turning to his family doctor to get answers. An ultrasound revealed there was something inside the back of his head that looked like a cyst.

After an initial biopsy, Dan was referred to a surgeon at The Ottawa Hospital Cancer Centre. Another biopsy revealed the cyst was actually a mass. It was melanoma. “I was scared. Cancer had stripped my family of so much. I lost both of my two older brothers and my father to cancer. I feared for my life,” recalls Dan.

Unfortunately, the mass starting growing – and it was growing fast. By the end of July, just two months later, the mass went from being not visible on the back of his head, to the size of a golf ball.

His surgical oncologist, Dr. Stephanie Obaseki-Johnson, initially wanted to shrink the tumour before surgery to remove it. However, the mass was growing too quickly.

Oncologist Dr. Michael Ong of The Ottawa Hospital in a patient room.
Dan Collins with Oncologist Dr. Michael Ong.

Time to act

On August 11, 2015, Dan had surgery that lasted most of the day. When it was over, he had 25 staples and 38 stitches in the back of his head. As he recovered, Dan was reminded of a saying that helped him through recovery, “Never be ashamed of your scars. It just means you were stronger than whatever tried to hurt you.”

He would need that strength with the news that awaited him. Only two weeks later, the mass was back. His doctors also discovered a mass in his right lung and shadows in the lining of his belly. He had stage 4 cancer – it had metastasized. This was an aggressive cancer that left Dan thinking about the family he had already lost and what would happen to him.

The next generation of treatment

Soon, he was introduced to The Ottawa Hospital’s Dr. Michael Ong and was told about immunotherapy – the next generation of treatment, with the hope of one day eliminating traditional and sometimes harsh treatment like chemotherapy. Dr. Ong prescribed four high doses of immunotherapy. At the same time, radiation treatment began for Dan – 22 in all. His immunotherapy treatments were three weeks apart at the Cancer Centre and between each, he would have an x-ray to monitor the tumours.

“Each x-ray showed the tumours were getting smaller. That’s when the fear started shifting to hope.” – Dan Collins, patient

By December 2015, Dan finished immunotherapy treatment and the next step was to wait. “This transformational treatment was designed to train my own immune system to attack the cancer. We would have to be patient to see if my system would do just that,” says Dan.

While the shadows in Dan’s stomach lining had shrunk, the mass in his lung had not. That’s when Dr. Ong prescribed another immunotherapy drug that would require 24 treatments.

Dan learned from his oncologist that melanoma has gone from being an extremely lethal cancer, with few treatment options, to having many different effective therapies available.

“When I started as an oncologist a decade ago, melanoma was essentially untreatable. Only 25 percent would survive a year. Yet now, we can expect over three quarters of patients to be alive at one year. Many patients are cured of their metastatic cancer and come off treatment. We are now able to prevent 50 percent of high-risk melanoma from returning because of advances in immunotherapy,” says Dr. Ong.

Dan completed his last immunotherapy treatments in September 2017.

Oncologist Dr. Michael Ong posing with armed crossed at The Ottawa Hospital.
Oncologist Dr. Michael Ong of The Ottawa Hospital.

Today, there is no sign of cancer

When Dan thinks back to the day of his diagnosis, he remembers wondering if he was going to die. “I believe I’m here today because of research and because of those who have donated to research before me.”

He thinks back to when his older brother Rick died of cancer in 2007. “At the time he was treated, his doctor asked if he would participate in a research study. The doctor told him directly, this would not help him, but it would help somebody in the future.” Dan pauses to reflect and then continues, “I like to think, that maybe, he had a hand in helping me out today. Maybe he helped me survive. One thing I do know is that research was a game changer for me.”

The Ottawa Hospital has been a leader in bringing immunotherapy to patients. Research and life-changing treatments available at The Ottawa Hospital altered Dan’s outcome and he hopes that advancements will continue to have an impact on many more patients, not only here at home but right around the world.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Update: September 2023

“As a prostate cancer survivor, I raise awareness and promote PSA testing to men. When I was first diagnosed, I was completely unaware I had a problem. I was leading a happy energetic life with my wife Jan. Thankfully, my doctor noticed the cancer through the simple PSA blood test.

The blessing is that I was diagnosed early and treated at The Ottawa Hospital quickly and effectively.

My journey does not stop here. I now promote awareness wherever and whenever possible. We have a local support group called the “Black Walnut Group” that spreads awareness and raises funds to support research, and I raise funds for cancer research at The Ottawa Hospital during Tamarack Ottawa Race Weekend.

Each September, the Winchester District Memorial Hospital (my local hospital that is connected to The Ottawa Hospital) hosts a PSA Event where men can come to learn about prostate cancer plus get free PSA test. Last year we had 117 men participate with 20 men being contacted for follow up. This year we had 219 men participate. Too many men continue to go undiagnosed when all it takes is a simple blood test.

I think it’s so important for men like me who have had prostate cancer to open up and talk about it. We also need to continue to support research at The Ottawa Hospital. Once you become aware of the great team of doctors here at The Ottawa Hospital, you want to do as much as possible to assist them in their research programs.”

— Tom Clapp

Published: February 2020

Tom Clapp didn’t have any symptoms. He thought he was ‘perfectly healthy’. So, it came as a surprise when a routine prostate-specific antigen (PSA) test revealed that he had an aggressive form of prostate cancer. But a clinical trial at The Ottawa Hospital saved his life. Today, he’s inspiring the community to give back and is raising awareness along the way.

An unexpected diagnosis

When a routine PSA test, a blood test typically used to screen for prostate cancer, came back higher than normal, Tom Clapp and his wife, Janet Clapp, had their concerns. But neither was prepared for the news they would receive back in February of 2009. It was prostate cancer, it was aggressive, and due to its location, it was inoperable. Tom and Janet were gutted. How could this be happening?

“I thought I was perfectly healthy,” explained Tom. “I didn’t have any symptoms.”

Tom was referred to The Ottawa Hospital and recommended for a clinical trial. His treatment plan was in place; he underwent 42 rounds of radiation, followed by two years of hormone treatment to stop the production of testosterone which was feeding his cancer. His latest tests and scans show he is cancer free.

Hearing the words “you have cancer” is never easy. But from the day of Tom’s diagnosis, he was inspired to make a difference and have a positive impact on the lives of those in our community living with cancer. It was a conscious decision to take positive action during a time when he otherwise felt very little control over how cancer was affecting him.

“On the day he was diagnosed Tom said, ‘This is a gift. Now that I have this, I can talk about it with others’,” said Janet. Janet didn’t know it at the time, but Tom would go on to make a significant difference in the lives of countless individuals through raising both awareness and funds for prostate cancer research and care. His impact has been significant and it started with three of his closest friends.

Tom Clapp, prostate cancer survivor with friends
Tom (center) and his wife Janet (far left) with members of the Eastern Ontario Prostate Cancer Awareness Committee.

After receiving his diagnosis, Tom encouraged three friends to get their first PSA test. When the results came in, all three of them were diagnosed with prostate cancer. Today they are all alive and well. Tom’s simple act of encouraging his friends to get tested could very well have saved their lives.

Raising awareness

This experience solidified Tom’s passion for raising awareness for prostate cancer and not a day goes by that he doesn’t think about it. Having been diagnosed when he was otherwise healthy, Tom knows firsthand the importance of regular checkups and testing.

“Too many men go untested, unaware that a simple blood test can lead to a diagnosis that might save their life,” explained Tom.

Tom pays tribute to his local family doctor, Dr. John Burke, for monitoring the results of his PSA test which raised concerns, resulting in a follow up at The Ottawa Hospital.

Tom’s own diagnosis, and his drive to raise awareness is what led him to play an instrumental role in developing what is known as the Eastern Ontario Prostate Cancer Awareness Committee (EOPCAC), as well as the Black Walnut Group, a support group for men who have been diagnosed, and their partners.

Strength in numbers

Once Tom received his diagnosis, he made a point to share his experience. He put his story in the local paper, organized a prostate cancer information session, spoke out at a community breakfast, and even went so far as to offer his phone number to those who were going through the same experience. If anyone needed someone to talk to, Tom wanted to be there for them. Over time, his phone started to ring more often. A great number of community members were opening up and sharing their experience with him. Tom recognized there was a real need and wanted to do more.

It was then that Tom suggested they start a support group. Everyone jumped on board. They planned their first meeting and in 2012 EOPCAC was born.

Getting out into the community

It wasn’t long before EOPCAC started raising awareness for prostate cancer in their community. “We have over 50 wellness days per year where we go out and raise awareness for prostate cancer,” said Tom. Over time, more people became aware of their group. Once the word got out, many were interested in not only joining, but also supporting it financially.

Dare to Flash a Stash

Simply getting out in to the community and raising awareness wasn’t enough for EOPCAC. They were determined to make a difference by giving back, too.

“Everyone in our group has had incredible treatment at The Ottawa Hospital,” said Tom. “We all have glowing reviews. So, we wanted to give back in some way. We decided to start a fundraiser.”

Wanting to support local prostate cancer care and research, EOPCAC organized a fundraiser they call Dare to Flash a Stash, in collaboration with the Winchester District Memorial Hospital Foundation. Members of EOPCAC decided to grow their moustaches to raise money and awareness for prostate cancer research and care.

It’s clear that they have their whole community supporting them along the way. “It feels like everywhere I go, when someone recognizes me, they hand me a generous gift in support of our fundraiser,” said Tom.

Even a local Cornwall brewery, Rurban Brewery, has pitched in by printing a moustache and ‘Dare to Flash a Stash’ on a can of beer to help raise awareness and funds. To date, this initiative has raised close to $185,000. Each year funds are distributed across various prostate cancer awareness, care and research initiatives, including The Ottawa Hospital.

There for each other

Seven years later, the committee is going strong. Members meet each month to support one another, as well as to brainstorm, strategize and plan how best to raise even more awareness and funds. As Tom thinks back to his life before his diagnosis, he exclaims, “Until I was diagnosed, I didn’t pay much attention. I didn’t think this would happen to me. It wasn’t on my radar. I don’t want others to make the same mistake that I did.”


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Immunotherapy provides a second chance after dire lung cancer diagnosis

As a lawyer, Andrea Redway has worked on international initiatives relating to justice reform. She’s travelled the world tackling big projects and has always been ready to face new challenges head-on—but nothing could have prepared Andrea for a stage 4 lung cancer diagnosis. This diagnosis rocked her world and left her wondering how long she would survive.

The first signs of trouble appeared in January 2015 when Andrea developed a cough that persisted. In March, she left on a work trip abroad. It was an exciting career opportunity with the added bonus of being able to bring her husband and two children, who were 8 and 11 at the time. Three weeks after returning home, the cough continued and she couldn’t shake her jet lag. “Usually I’m over jet lag in a week. I was still so exhausted, and thought maybe I had pneumonia,” recalls Andrea.

“Here I was, 47 years old and I had no risk factors. I would never have thought that I could get lung cancer.” – Andrea Redway

Grim diagnosis

With no family doctor, she went to a walk-in clinic and was prescribed antibiotics. Within a few days, she started noticing other symptoms. “I had strange pains in my leg and then some cramping in my abdomen. The exhaustion continued.”

Andrea received a referral to a family doctor and an x-ray was ordered. The results showed a large mass on her lung. Within a week, she received the grim diagnosis—stage 4 lung cancer. The cancer had already spread to her bones, adrenal glands, brain and there were early signs of it in her colon. She was shocked beyond belief. “Here I was, 47 years old and I had no risk factors. I would never have thought that I could get lung cancer.”

Andrea Redway and family
Andrea, husband Michael Cayley, with their two children in Tofino, B.C. post diagnosis.

All Andrea and her husband could think about was getting on treatment right away. She had to, for the sake of her children.

She was referred to Dr. Garth Nicholas, an oncologist at The Ottawa Hospital and began chemotherapy treatment along with a small amount of radiation. Six weeks later, a scan revealed the chemotherapy was only partially working.

Clinging to life

Dr. Garth Nicholas at The Ottawa Hospital
Dr. Garth Nicholas is an oncologist at The Ottawa Hospital

Dr. Nicholas was aware of a new clinical trial, published in the New England Journal of Medicine. It was an immunotherapy treatment specifically used to treat stage 4 lung cancer, but it wasn’t yet available in Canada. He applied for the compassionate care program with the drug company and Andrea was given one dose of the drug, Nivolumab. Today, Nivolumab is now routinely used to treat many people with lung cancer. It is also used to treat other cancers, most notably melanoma.

But Andrea’s cancer continued to progress and she became very sick. Back in hospital, it was discovered that she had a perforated bowel. She recalls the situation being dire, “I needed emergency surgery or that was going to be the end of the line for me.”

Given the progression of Andrea’s cancer, it was uncertain if surgery was a viable option, but her care team at The Ottawa Hospital wanted to give Andrea the chance to have more time with her family. “Dr. Guillaume Martel, who is my saviour, did the surgery. Here I am today as a result,” says Andrea.

Once she recovered from surgery, Andrea was able to resume treatment to take on the cancer, which had ravaged her body. One month later, she received her second dose of immunotherapy. “I continued with immunotherapy for about two years. I completed my treatment in September 2017 and I’ve been great ever since.”

“Everything else is gone. It’s amazing—totally amazing. With little kids, we’ve had so many special moments since then.” – Andrea Redway

Eight months after starting treatment, Andrea’s scan showed the cancer was gone from outside of her lungs and the primary tumour on her lung had shrunk to about half. “When the tumour showed up on the scan originally, it was six centimeters. Now, it’s about 2.5 centimeters. It’s been described as mostly necrotic or dead.”

Transformational results

While Andrea did experience side effects like fatigue, dry eyes and joint pain, she says it was a small price to pay because immunotherapy was a game changer. “Everything else is gone. It’s amazing—totally amazing. With little kids, we’ve had so many special moments since then.”

Dr. Nicholas explains how much cancer treatment has improved in just four years since Andrea’s initial diagnosis. “Immunotherapy has become a standard part of the treatment of lung cancer over the past four years or so. There are rare patients like Andrea for whom it is an extraordinarily effective treatment, much better than any other therapy we’ve had in the past.”

However, Dr. Nicholas adds that not every lung cancer patient has a positive response like Andrea, and more research needs to be done. “There is a lot of ongoing research into why some tumours respond to immunotherapy while others do not, and whether we can do anything to alter non-responding tumours in order to make them respond.”

Today, Andrea continues to embrace those special moments, grateful to be watching her children grow.


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

In late 2019, an ovarian cancer study that took place at The Ottawa Hospital made headlines across Canada. It suggests that metformin, a medication commonly used to treat Type 2 diabetes, may hold promise for helping prevent ovarian cancer. This study was possible in part thanks to a retired Ottawa educator, Margaret Craig, who believed that research could beat the disease that would eventually take her life.

Margaret, who went by Peg to her family, was diagnosed with ovarian cancer in Tucson, Arizona, just a few days before Christmas 2013.

She hadn’t been feeling well for a couple of months, but couldn’t quite pinpoint what was wrong, other than a failure to lose the couple of pounds she had gained, despite trying, and a slight swelling and firmness in her abdomen.

She decided to visit a walk-in-clinic after she had difficulty breathing. The clinic sent Margaret to an emergency department, where she was diagnosed with ovarian cancer.

The news left her reeling.

“Part of that was because I had to get back to Ottawa and it was Christmas,” she said in an interview in 2015. “But I got here. I caught a flight in a snowstorm on the busiest travel day of the year, December 22.”

Margaret immediately went to The Ottawa Hospital, where doctors confirmed the diagnosis. She began treatment in January.

“Peg would have been so happy with this result. It’s exactly the kind of cutting-edge research into ovarian cancer she would have wanted. It also gives me a sense of closure regarding Peg’s death.” — Holly Craig, Margaret’s sister

Ovarian cancer hides in plain sight

Margaret Craig
Margaret speaking at the Teas, Talks, and Tours symposium

“I have been told over and over again by the professionals that it is rare to detect ovarian cancer early,” said Margaret. “Mine was caught early enough that they could surgically remove everything that was over a centimeter.”

Margaret learned that there are often no obvious symptoms until the disease is advanced, and no reliable screening test to catch it early.

Ovarian cancer is the fifth most common cancer in women, and among the deadliest, with a five-year survival rate of 45 percent. But researchers at The Ottawa Hospital, backed by the generosity of people like Margaret, are committed to changing these statistics for good.

Grateful for compassionate care

Margaret was so grateful for the compassionate treatment she received at The Ottawa Hospital that she was inspired to give back by investing in cancer research that could help people like her in the future.

She enlisted the help of her sister Holly Craig, a retired university professor and researcher living in Arizona. They spoke at length about Margaret’s desire to support innovative research in her will. Margaret asked Holly to find her a Canadian researcher who was doing groundbreaking work in ovarian cancer.

Holly identified Dr. Barbara Vanderhyden, a senior scientist at The Ottawa Hospital and the Corinne Boyer Chair in Ovarian Cancer Research at the University of Ottawa.

“It was clear that Dr. Vanderhyden was doing innovative research,” said Holly. “I liked her, and I liked her questions.”

Innovative research inspires gift in will

Dr. Barbara Vanderhyden, The Ottawa Hospital
 Dr. Barbara Vanderhyden

Holly flew to Ottawa to tour Dr. Vanderhyden’s lab with Margaret and learn more about her research. Margaret was particularly interested in Dr. Vanderhyden’s innovative and bold ideas. The visit convinced Margaret to make a gift in her will.

Dr. Vanderhyden sat with Margaret during her last chemotherapy treatment at The Ottawa Hospital, and was there when she rang the bell to mark the end of her treatment.

On June 2016, Dr. Vanderhyden invited Margaret to speak at an educational symposium called Teas, Talks and Tours she had organized for ovarian cancer patients and their families and friends.

“She was a private person, but she was willing to speak at Dr. Vanderhyden’s event,” said Holly. “That was a big step for her.”

At the symposium Margaret met Dr. Curtis McCloskey, a talented, capable young researcher on Dr. Vanderhyden’s research team who showed deep appreciation for her gift to research.

When Margaret reached her last few days, each day Dr. Vanderhyden would have one person on her team write a short story about the impact of Margaret’s donation on their work. Then Dr. Vanderhyden would send these daily stories to Margaret, so that she might be comforted by the legacy that she was leaving behind.

Margaret died from ovarian cancer in September of 2016, and Dr. Vanderhyden was asked to give the eulogy at her funeral.

Gift to cancer research bears fruit

Margaret’s generous gift has been put to good use. In 2019, Dr. McCloskey and Dr. Vanderhyden published a study that offers a new hypothesis about how ovarian cancer forms and suggests how it might be prevented.

The study is the first to show that the natural stiffening of the ovaries called fibrosis occurs with age. It also suggests that the diabetes drug metformin may be able to halt this process.

“We hope that someday metformin may prove to be an effective preventative treatment for younger women who are at high risk of ovarian cancer, but who can’t have their ovaries removed because they still want to have children,” said Dr. Vanderhyden. “We are so grateful to donors like Margaret who believe that research is the way forward.”

Holly and the rest of Margaret’s family are thrilled with the impact of Margaret’s gift.

“Peg would have been so happy with this result. It’s exactly the kind of cutting-edge research into ovarian cancer she would have wanted,” said Holly. “It also gives me a sense of closure regarding Peg’s death.”

Hospital staff with a banner thanking a patient

“The Ottawa Hospital is a leading academic health, research and learning hospital proudly affiliated with the University of Ottawa.”


The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.